presented the results of a phase I clinical study investigating the safety, efficacy, and pharmacokinetics of genetically modified CD7-targeting allogeneic CAR-T cell therapy (RD13-01) in patients with R/R CD7-positive hematological malignancies. The gene discussed is CD7; the disease is hematologic disorder.